Abstract
Current pharmacologic treatment of osteogenesis imperfecta (OI) consists of agents studied in and developed for use in osteoporosis. New agents under study for use in osteoporosis may also benefit patients with OI. In this chapter we review recommendations for current dietary supplements and the potential of several new anabolic and anti-resorptive agents for use in OI, including recombinant parathyroid hormone, sclerostin antibodies, strontium ranelate, RANK-ligand inhibitors, and cathepsin K inhibitors. While many of these agents may prove beneficial to patients with OI, optimal therapies for the future will target the specific collagen mutations underlying the disorder.
Original language | English (US) |
---|---|
Title of host publication | Osteogenesis Imperfecta |
Subtitle of host publication | A Translational Approach to Brittle Bone Disease |
Publisher | Elsevier Inc. |
Pages | 519-525 |
Number of pages | 7 |
ISBN (Print) | 9780123971654 |
DOIs | |
State | Published - Sep 2013 |
Keywords
- Bisphosphonates
- Bone remodeling
- Cathepsin K
- Parathyroid hormone
- Pharmacology
- RANK ligand
- Sclerostin
- Vitamin D
- Wnt
ASJC Scopus subject areas
- General Dentistry
- General Medicine